ProfileGDS5678 / 1450388_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 65% 65% 65% 68% 65% 49% 59% 68% 68% 68% 63% 65% 65% 63% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.9176765
GSM967853U87-EV human glioblastoma xenograft - Control 23.9010865
GSM967854U87-EV human glioblastoma xenograft - Control 33.9298965
GSM967855U87-EV human glioblastoma xenograft - Control 44.1776368
GSM967856U87-EV human glioblastoma xenograft - Control 53.9071465
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.2576449
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.6368259
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.1324668
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.1841368
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.1853868
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.7618163
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.9104765
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.9156265
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.7419363